What do the BPC-157 and TB-500 literatures have in common?

The short answer

Answered from published research literature only. It describes what that literature examines; it is not a statement about use in people. BPC-157 and TB-500 are investigational research material and are not approved products.

Both are examined in tissue-repair and extracellular-matrix models, which is why the two are frequently discussed together.2103067212852258

They are different molecules examined through different mechanisms. BPC-157 work centres on nitric-oxide–system signalling and vessel formation; the beta-thymosin literature centres on actin binding and matrix remodelling.2378214526006229

Cited literature

1. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationChang CH, et al. · Journal of Applied Physiology · 2011PMID 21030672 ↗
2. Thymosin beta 4 interactionsBubb MR · Vitamins and Hormones · 2003PMID 12852258 ↗
3. BPC 157 and blood vesselsSeiwerth S, et al. · Current Pharmaceutical Design · 2014PMID 23782145 ↗
4. Potential role of thymosin Beta 4 in liver fibrosisKim J, et al. · International Journal of Molecular Sciences · 2015PMID 26006229 ↗

Research-literature characterization, provided for research context only. For laboratory research use only. Not for human consumption.

Where to read more

• BPC-157: identity and cited literature
• TB-500: identity and cited literature
• BPC-157 product page
• TB-500 product page
• BPC-157 certificate of analysis
• TB-500 certificate of analysis